Managing Multiple Myeloma Complications: Renal Failure, Bone Disease, and Infections
Release Date: October 02, 2014
Expiration Date: October 02, 2015
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
While therapeutic approaches for multiple myeloma have improved significantly in recent years, patients with this disease are still at risk for developing potentially severe disease-related complications, including renal impairment, bone disease and infection. These complications must be proactively monitored for and treated, to prevent worsening of disease. In this focused activity, Dr. Ann Mohrbacher addresses specific therapeutic interventions to reduce skeletal complications, to prevent renal injury and reverse it when it does occur, and to minimize the risk of infections in patients with multiple myeloma.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in the management of patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- List specific interventions for renal impairment, bone disease and infection
Complications: Renal Failure, Bone Disease, and Infections – Ann F. Mohrbacher, MD
Instructions for Participation and Credit
This activity is eligible for credit through October 2, 2015. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Ann F. Mohrbacher, MD
Associate Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Los Angeles, California
Dr. Ann Mohrbacher received her medical degree from Harvard Medical School and completed an internship and residency in internal medicine at Brigham & Women’s Hospital. In addition, she was a fellow in clinical oncology/tumor immunology at the Dana-Farber Cancer Institute. Dr. Mohrbacher is currently an associate professor of clinical medicine at Keck School of Medicine, University of Southern California in Los Angeles.
A devoted educator, researcher and medical practitioner, Dr. Mohrbacher is board certified in medical oncology and internal medicine. She is a member of the Massachusetts Medical Society, the American Society of Hematology, and the Southwest Oncology Group, and is on the Board of Directors of the California Lymphoma Group. Dr. Mohrbacher has been published in a number of medical journals and has been invited to lecture on topics including radioimmunotherapy of non-Hodgkin’s lymphoma and B-cell targeted therapy of rheumatoid arthritis. Her major areas of research interest include trials of novel clinical agents to treat hematologic malignancies; immunotherapy of hematologic malignancies with monoclonal antibodies and antitumor vaccines; and blood stem cell transplantation in lymphoma, leukemia and multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-025-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Ann Mohrbacher has received honoraria related to the development of educational materials from Celgene Corporation, as well as speakers’ bureau activities from Genentech, Inc. and Millennium: The Takeda Oncology Company.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Mohrbacher has indicated that she does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Mohrbacher has indicated that she does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft®Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.